NeuBase Therapeutics Inc. (Formerly Ohr Pharmaceutical Inc.)

United States of America Country flag United States of America
Sector: Specialty Finance
Ticker: NBSE
Factsheet Factsheet

Levered/Unlevered Beta of NeuBase Therapeutics Inc. ( NBSE | USA)

Beta is a statistical measure that compares the volatility of a stock against the volatility of the broader market, which is typically measured by a reference market index. Since the market is the benchmark, the market's beta is always 1. When a stock has a beta greater than 1, it means the stock is expected to increase by more than the market in up markets and decrease more than the market in down markets. Conversely, a stock with a beta lower than 1 is expected to rise less than the market when the market is moving up , but fall less than the market when the market is moving down. Despite being rare, a stock may have a negative beta, which means the stock moves opposite the general market trend.
NeuBase Therapeutics Inc. shows a Beta of 1.85.
This is higher than 1. The volatility of NeuBase Therapeutics Inc. according to this measure is higher than the market volatility.

Beta (Ref: NASDAQ 100)
Levered betaUnlevered beta
1-Year1.852.47
2-Year1.502.00
3-Year1.491.99
More...
Valuation
EV/EBITDA LastEV/EBITDA(e) 2021EV/EBITDA NTM
NeuBase Therapeutics Inc.Free trialFree trialFree trial
International PeersFree trialFree trialFree trial
Specialty Finance4.729.579.74
NASDAQ 10022.6416.7615.99
United States of America2.049.839.20
More...
Stock Perf excl. Dividends (in USD)
NBSENASDAQ 100Rel. Perf.
Year-to-Date-44.4%20.7%-65.1%
1-Week-4.2%1.0%-5.2%
1-Month-2.0%1.5%-3.5%
1-Year-53.7%35.2%-88.9%
3-Year-11.6%127.1%-138.7%
5-Year-93.4%220.1%-313.5%
More...
International Peers - NeuBase Therapeutics Inc.
Company NameCtryMarket
Cap.
last (mUSD)
NeuBase Therapeutics In...USA127
International Peers Median0.84
AVEO Pharmaceuticals In...USA228
Kala Pharmaceuticals In...USA117
Aerie Pharmaceuticals I...USA469
Ocular Therapeutix Inc.USA544
KalVista Pharmaceutical...USA400
GPRV Analysis
NeuBase Therapeutics...
Intl. Peers
U.S Patents No. 7,882,001 & 8,082,201
More...
Net Sales Chart
More...
Quotes Chart

1-Year Rebased Stock Chart

  • NeuBase Therapeutics Inc.
  • NASDAQ 100
More...

Did you know ?

Infront Analytics' Beta calculator allows you to define your input parameters for custom beta calculations.
The beta calculator offers additional flexibility, such as:
- Reference index: apply the same reference index for all companies in your list regardless of their country.
- Sampling frequency: choose between a weekly or a monthly sampling frequency for the closing prices.
- Debt for unlevered beta: choose the type of debt to be used for unlevered beta calculations.
- Additional beta statistics: calculate R-squared and T-value.

About Beta

Standard beta is co-called levered, which means that it reflects the capital structure of the company (including the financial risk linked to the debt level). Unlevered beta (or ungeared beta) compares the risk of an unlevered company (i.e. with no debt in the capital structure) to the risk of the market. Unlevered beta is useful when comparing companies with different capital structures as it focuses on the equity risk. Unlevered beta is generally lower than the levered beta. However, unlevered beta could be higher than levered beta when the net debt is negative (meaning that the company has more cash than debt).
Many different betas can be calculated for a given stock. The main common variables that affect beta calculations are the time period, the reference date, the sampling frequency for closing prices and the reference index.
The calculation divides the covariance of the stock return with the market return by the variance of the market return. Beta is used very often for company valuation using the Discounted Cash Flows (DCF) method. The discount rate is calculated using the Weighted Average Cost of Capital (WACC). The WACC is essentially a blend of the cost of equity and the after-tax cost of debt. The cost of equity is usually calculated using the capital asset pricing model (CAPM), which defines the cost of equity as follows: re = rf + β × (rm - rf)
Where:
rf = Risk-free rate
β = Beta (levered)
(rm - rf) = Market risk premium.